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One-sentence summary: Nanoscale reorganization of TNFR1 within the plasma membrane 
promotes the activation of distinct signaling pathways. 
 
Editor’s summary: 
Organizing TNFR1 signaling 
The inflammatory cytokine tumor necrosis factor a (TNF-a) stimulates both cell death and 
survival by activating its ubiquitously expressed membrane receptor, TNFR1. Morton et al. used 
various microscopy techniques to investigate TNFR1 membrane organization. In resting cells, 
TNFR1 was found within clusters that required its cytoplasmic tail. After TNF-a binding, TNFR1 
clusters were denser and moved within the membrane more rapidly, which correlated with the 
activation of specific downstream pathways and physical association with the kinase MEKK1. 
Experiments with engineered ligands that could only bind a specific number of TNFR1 molecules 
suggested that engagement of two receptors was sufficient for signaling, but that trimeric 
interactions were necessary for extracellular conformational changes in TNFR1. These findings 
suggest how membrane organization alters TNFR1 signaling, insights that may direct the 
























Signaling	 by	 the	 ubiquitously	 expressed	 tumor	 necrosis	 factor	 receptor	 1	 (TNFR1)	 after	
ligand	binding	plays	an	essential	role	in	determining	whether	cells	exhibit	survival	or	death.	
TNFR1	 forms	 distinct	 signaling	 complexes	 that	 initiate	 gene	 expression	 programs	
downstream	 of	 the	 transcriptional	 regulators	 NF-κB	 and	 AP-1	 and	 promote	 different	
functional	 outcomes,	 such	 as	 inflammation,	 apoptosis,	 and	 necroptosis.	 Here,	 we	




trimeric	 TNF-α	 binding,	 TNFR1	 clusters	 underwent	 a	 conformational	 change,	 which	
promoted	 lateral	mobility,	 their	association	with	the	kinase	MEKK1,	and	activation	of	 the	
JNK/p38/NF-κB	 pathway.	 These	 phenotypes	 required	 a	minimum	 of	 two	 TNFR1–TNF-α	
contact	sites;	fewer	binding	sites	resulted	in	activation	of	NF-κB	but	not	JNK	and	p38.	These	










oligomers	 on	 the	 cell	 surface,	mediated	 by	 the	 pre-ligand	 assembly	 domain	 (PLAD)	 that	
resides	 within	 the	 N-terminal	 CRD1	 that	 is	 not	 directly	 involved	 in	 ligand-binding	 (3).	
Soluble	PLAD	can	prevent	TNFR	signaling	and	inhibit	inflammatory	arthritis,	suggesting	that	
PLAD-mediated	 receptor	 assembly	 is	 required	 for	 TNFR	 signaling	 (4).	 	Mutations	within	
CRD1	and	CRD2	that	are	thought	to	render	TNFR1	constitutively	active	are	also	associated	
with	the	inflammatory	disease	TNF	Receptor	associated	periodic	syndrome	(TRAPS)	(5,	6).	




to	 receptor	 signaling	 within	 intact	 cells	 remains	 unclear	 as	 do	 the	 potential	 molecular	
changes	in	TNFR1	that	occur	in	response	to	different	context-dependent	stimuli.	
	
TNFR1	 also	 contains	 a	 Death	 Domain	 (DD)	within	 cytoplasmic	 tail	 that	 recruits	 adaptor	
molecules	 leading	 to	 the	 assembly	 of	 signaling	 complexes	 (I	 and	 IIa/b/c)	 that	 promote	
distinct	 functional	 outcomes	 (10).	 After	 TNF	 binding,	 complex	 I	 is	 assembled	 at	 TNFR	
















TNFR1	 is	 proposed	 to	 be	 a	 pre-formed	 dimer	 at	minimum,	 but	 assumed	 to	 form	 higher	
ordered	 clusters	 on	 ligand	 binding	 in	 order	 to	 initiate	 signaling	 (3).	 Furthermore,	
cholesterol-rich	 lipid	 raft	 domains	 and	palmitoylation	modifications	may	be	 required	 for	
TNFR1	 signaling	 after	 ligand	 binding	 by	 promoting	 coalesce	 of	 pre-assembled	 TNFR1	
clusters	to	form	functional	signaling	platforms	(14,	15).	However,	lipid	rafts	are	not	required	
for	TNFR1-induced	NFκB	signaling	responses	to	ligand	(16,	17).	Given	the	essential	role	of	
TNFR1	 in	 mediating	 cell	 behavior	 under	 homeostatic	 and	 inflammatory	 conditions,	
understanding	the	way	in	which	TNFR1	assembles	and	signals	at	the	plasma	membrane	is	of	
central	importance	to	defining	the	role	of	this	receptor	in	disease	settings.	Here	we	employed	
a	 combination	 of	 biochemical	 and	 advanced	microscopy	 approaches	 in	 adherent	 cells	 to	
define	 the	 role	 of	 TNF-TNFR1	 interactions	 in	 promoting	 receptor	 clustering	 and	 specific	
signaling	events.	Our	 findings	revealed	 that	TNFR1	 formed	pre-assembled	clusters	at	 the	













fluorescence	 (TIRF)	microscopy.	 Images	demonstrated	 that	 in	 starved	HeLa	 cells,	TNFR1	
was	clustered	within	the	cytoplasm	around	the	peri-nuclear	region	with	small,	irregularly	
positioned	 clusters	 of	 TNFR1	 at	 the	 plasma	 membrane	 (Fig	 S1A).	 This	 pre-clustered	
localization	 of	 TNFR1	 at	 the	 plasma	 membrane	 was	 also	 observed	 in	 a	 range	 of	 other	
adherent	 cell	 types	 (Fig	S1B).	 In	order	 to	allow	us	 to	 study	 the	behavior	of	 these	TNFR1	
clusters	in	live	cells,	we	generated	TNFR1	knockdown	HeLa	cells	(Fig	S1C)	and	re-expressed	
full-length,	wild-type	(WT)	TNFR1-GFP	in	these	cells.	Expressed	TNFR1-GFP	bound	to	TNFa	
(Fig	 S1D),	 showed	 very	 similar	 co-localization	 at	 the	 plasma	 membrane	 as	 endogenous	












formed	 clusters	 at	 the	 plasma	membrane,	we	 expressed	 three	 different	mutant	 forms	 of	
TNFR1-GFP	 in	 TNFR1	 knockdown	 cells:	 R92Q	 (within	 CRD2)	 or	 C52F	 (within	 CRD1),	
previously	characterized	in	patients	with	TRAPS	(18),	as	well	as	a	quadruple	point	mutation	
within	 CRD1	 predicted	 to	 destabilize	 putative	 pre-formed	 associations	 through	 CRD1	
(Q17A/K19A/H34A/D49A).	When	we	compared	the	distribution	of	each	receptor	mutant	to	
WT	 TNFR1	 by	 TIRF	 microscopy,	 we	 found	 no	 substantial	 change	 in	 plasma	 membrane	
clustering	with	 any	of	 the	mutants	 compared	 to	WT	TNFR1	 (Fig	1B).	We	 also	 expressed	






preferentially	 co-associate	 into	membrane	 clusters.	 This	 data	 suggests	 that	 formation	 of	
TNFR1	clusters	 in	 the	 absence	of	 ligand	may	not	depend	on	previously	 reported	 regions	










binding	 (Fig	 1D)	 that	 corresponded	 with	 a	 shift	 to	 lower	 lifetimes	 across	 the	 receptor	





Nanoscale	 organization	 of	 TNFR1	 pre-assembled	 clusters	 changes	 following	 ligand	
binding	
Our	 FRET	 data	 demonstrated	 that	 TNFR1	 homo-oligomerization	 increases	 following	
TNFa treatment,	but	without	changes	in	the	overall	cluster	size	or	number	by	diffraction-
limited	microscopy.	In	order	to	determine	whether	TNFR1	may	undergo	exchange	between	
discrete	 clusters	 during	 activation	 to	 drive	 this	 increased	 homo-oligomerization,	 we	
performed	 fluorescence	 recovery	 after	 photobleaching	 (FRAP)	 analysis	 of	 cells	 co-
expressing	TNFR1-GFP	and	TNFR1-mRFP.	TNFR1-GFP	was	bleached	and	recovery	analyzed	
following	TNFa	stimulation	whilst	simultaneously	following	the	unbleached	TNFR1-RFP	to	
accurately	 track	 the	 cluster.	 Recovery	 curves	 demonstrated	 no	 new	 TNFR1-GFP	 was	
recruited	 to	 clusters	 following	 activation	 (Fig	 2A).	 These	 data	 suggest	 that	 there	 is	 no	
detectable	 exchange	 of	 receptors	 between	 clusters	 following	 ligand	 binding.	 To	 further	
define	 the	 potential	 changes	 to	 TNFR1	 organization	 within	 clusters,	 we	 used	 stochastic	
	 5	
optical	 reconstruction	microscopy	 (STORM)	 to	 quantify	 positioning	 of	 individual	 TNFR1	






















was	 not	 required	 for	 TNFR1	 activation,	 we	 treated	 cells	 with	 the	 Dynamin2	 inhibitor	
Dynasore	 and	 analyzed	 activation	 of	NFκB	 and	 JNK.	 Inhibiting	Dynamin	 function	 had	 no	
impact	on	activation	of	either	pathway	(Fig	3D)	or	localization	of	TNFR1	(Fig	S3C).	These	
data	demonstrated	 that	 endocytosis	 did	not	 play	 a	 role	 in	TNFR1	activation	under	 these	
conditions	tested	in	adherent	cells	and	is	therefore	unlikely	to	account	for	the	TNFR1	cluster	
movement	we	observed.	We	also	addressed	the	possibility	that	TNFR1	ectodomain	cleavage	
may	 contribute	 to	 cluster	 movement,	 as	 TNFR1	 has	 previously	 been	 show	 to	 undergo	
cleavage	 within	 the	 ectodomain	 by	 the	 enzyme	 TACE	 (25,	 26).	 However,	 western	 blot	
analysis	 for	TNFR1	cytoplasmic	domain	following	 ligand	stimulation	did	not	reveal	 lower	
molecular	 weight	 bands	 and	 no	 change	 in	 TNFR1	 banding	 pattern	 was	 seen	 after	 pre-
treatment	with	the	TACE	inhibitor	TAPI-0	(Fig	S3A).	These	data	indicated	that	TNFR1	does	




and	 subsequently	 promote	 signal	 transduction	 from	 the	 plasma	membrane	 in	 some	 cell	
















movement,	 we	 performed	 TIRF	 time-lapse	 analysis	 of	 cells	 expressing	 ΔCD-TNFR1.	 We	
observed	that	 in	comparison	to	WT	TNFR1,	plasma	membrane	 localization	of	 the	mutant	
receptor	lacking	the	cytoplasmic	region	was	increased.	Despite	this,	ΔCD	TNFR1	assembled	
clusters	that	exhibited	higher	basal	movement	and	did	not	alter	speed	in	response	to	ligand	
binding	 compared	 to	WT	TNFR1	 (Fig	 S3E).	 These	 data	 suggest	 that	 association	 between	














TNFR1	 cluster	 movement	 correlates	 with	 ligand-receptor	 interaction	 number	 and	
signaling		



























WT	 TNFR1	 homo-oligomerization.	 The	 data	 demonstrated	 that	 mBC	 TNFa	 induced	
significantly	 less	 TNFR1	 clustering	 compared	 to	mB	 ligand	 (Fig	 4C),	which	 suggests	 that	
TNFa	 binding	 to	 a	 single	 receptor	 was	 not	 sufficient	 to	 induce	 TNFR1	 interactions	 that	



















with	 TNFR1	 in	 all	 conditions,	 including	 cholesterol-depleted	 cells	 (Fig	 S6C).	 This	 data	
suggests	 that	 coupling	 between	TNFR1	 and	MEKK1	 correlates	with	TNFa-TNFR1	 cluster	
movement	in	adherent	cells	and	the	differential	activation	of	p38	and	JNK	(28).		
	




p38	 and	 JNK.	 However,	 the	 molecular	 changes	 within	 TNFR1	 clusters	 regulating	 this	
movement	and	capture	of	MEKK1	remain	unclear.	We	hypothesized	that	when	two	or	more	





no	 difference	 in	 receptor	 movement	 or	 clustering	 in	 response	 to	 ligand-binding	 in	 WT	
TNFR1	and	ΔCD	TNFR1	expressing	cells,	we	first	analyzed	the	potential	for	TNFa	to	induce	
changes	 to	WT	 or	 ΔCD	 TNFR1.	 FLIM	 analysis	 demonstrated	 a	 population	 TNFR1	was	 in	
proximity	to	the	plasma	membrane	in	unstimulated	cells,	with	no	differences	between	WT	
and	ΔCD	TNFR1	(Fig	5A).	However,	TNFa	stimulation	resulted	in	a	significant	increase	in	WT	














that	 can	 be	 triggered	 downstream	 of	 ligand	 binding	 to	 TNFR1.	 However,	 the	 very	 early	
events	that	occur	within	TNFR1	oligomeric	structures	that	dictate	these	signaling	decisions	





at	 the	 plasma	 membrane	 of	 adherent	 cells	 (summarized	 in	 Fig	 5C).	 These	 clusters	 are	
unchanged	in	PLAD	or	putative	dimerization	mutants	within	the	TNFR1	CRD1/2	domains	
but	 are	 less	 abundant	 following	 removal	 of	 the	 cytoplasmic	 domain.	 Although	 the	 PLAD	
domain	is	important	in	constitutive	dimerization	or	oligomerization	or	TNFR1	(3,	4,	18),	our	
data	would	 suggest	 that	 larger-scale	membrane	 assemblies	 of	 TNFR1	 are	 less	 reliant	 on	
PLAD	extracellular	domain	interactions.	Instead,	the	association	with	cytoplasmic	proteins	
through	the	presence	of	the	death	domain	may	play	a	more	important	role	in	this	process.	
Using	 both	 FRET/FLIM	 and	 STORM	 analysis,	 we	 showed	 this	 proximity	 was	 further	
increased	upon	binding	of	TNFa	to	pre-formed	clusters,	without	altering	the	overall	size	of	
the	clusters.	STORM	can	provide	molecular	mapping	of	molecules	at	the	~20nm	scale	and	
FRET	 enables	 detection	 of	 interactions	 below	 10nm	 (30,	 31).	 Whereas	 many	 molecular	
details	of	intact	TNFR1	are	well-described	(32),	the	potential	molecular	distances	within	pre-
formed	 or	 ligand-induced	 TNFR1	 groups	 have	 not	 been	 previously	 analyzed	 in	 intact	
adherent	cells.	Our	combined	high-resolution	imaging	approaches	have	therefore	provided	





















interactions	 between	 adjacent	 receptors	within	 these	 pre-formed	 clusters	 appears	 to	 be	
sufficient	to	induce	a	larger-scale	assemblies	which	correlate	with	receptor	activation,	as	has	
been	previously	 suggested	by	molecular	modelling	 experiments	 (32).	The	pre-assembled	
receptor	clusters	through	cytoplasmic	domain	interactions	would	provide	spatial	proximity	
sufficient	 to	engage	 two	 ligands	 simultaneously,	 thus	 initiating	 rapid	 receptor	movement	
and	 capture	 of	 specific	 signaling	molecules.	Our	 data	 further	 suggests	 that	 a	 single	TNF-
TNFR1	ligand	interaction	can	be	sufficient	to	induce	activation	of	NFκB	pathways,	but	not	
JNK	 and	 p38.	 Our	 data	 revealed	 that	 TNFR1	 cluster	movement	 strongly	 correlated	with	
increased	 colocalization	 between	 TNFR1	 and	 MEKK1,	 which	 can	 initiate	 p38	 and	 JNK	
signaling	following	stimulation	by	ligand	(28,	35).	Whereas	we	did	not	explore	activation	of	
every	potential	TNFR1-dependent	pathway	in	this	study,	our	data	implies	that	the	changes	
we	 observed	 are	 not	 required	 to	 trigger	 IKK	 signal	 initiation,	 and	 further	 suggests	 that	
differential	 ligand	 binding	 or	 receptor	 proximity	 may	 provide	 means	 to	 fine-tune	 the	
signaling	response	in	different	physiological	contexts.	Notably,	the	data	we	present	in	this	
study	focuses	on	the	effects	of	soluble	TNFα	on	adherent	cells.	However,	TNFα	is	can	also	
exist as a less well studied trimeric 26kDa membrane tethered form (mTNFα), which can elicit 
both shared and distinct bioactivities when compared to the 17kDa cleaved, soluble form (36). In 
contrast to soluble TNFα, mTNFα acts in a juxtacrine fashion through cell-cell contact, which may 
present the ligand to TNFR in a different conformation, as well as maintaining contact for a longer 
duration to initiate different signaling outcomes. Applying the approaches we present in the current 
study to analyze TNFR-mTNFα interactions in future may provide new insight into the shared and 






signaling	 in	response	to	 ligand	binding	(37,	38),	our	study	suggests	 that	 the	cytoskeleton	




membrane	 and	 whether	 additional	 factors	 or	 microdomains	 within	 the	 membrane	
contribute	to	cluster	stability.	However,	our	FRAP	data	showed	no	significant	movement	of	
receptors	 between	 clusters	 or	 internalization	 of	 TNFR1	with	 or	without	 the	 presence	 of	






needs	 to	 undergo	 additional	 conformational	 changes	 to	 increase	 receptor	 proximity,	
potentially	 at	 minimum	 as	 a	 dimer	 within	 a	 larger	 network,	 and	 this	 promotes	 cluster	
movement.	 Future	 studies	 will	 be	 aimed	 at	 defining	 the	 mechanisms	 that	 control	 this	
movement	 and	 how	 this	 relates	 to	 TNFR1	 conformational	 changes.	 Our	 study	 provides	
insight	into	the	assembly	requirements	on	both	sides	of	the	plasma	membrane	that	precedes	
TNFR1	 receptor	 movement	 and	 subsequent	 initiation	 of	 JNK/p38	 signaling	 cascades.	 In	
addition	to	demonstrating	differential	nanoscale	TNFR1	clustering	correlates	with	signaling	








Anti-TNFR1	antibody	 (Mab225)	was	 from	R&D	systems.	Anti-HA,	 anti-phosp65	 (ser576),	
anti-p65,	anti-phosJNK,	anti-JNK,	anti-phos-p38,	anti-p38,	anti-MLK3,	anti-MEKK1,	anti-RIP,	
anti-TRADD,	anti-TRAF2	and	anti-clathrin	antibodies	were	from	Cell	Signaling	Technology.		


























233.	 	 The	 construct	 was	 optimized	 for	 E.coli	 expression	 (GeneComposer™),	 synthesized	
(ATUM)	and	cloned	into	the	arabinose-inducible	expression	vector	pEMB54	adding	a	6His-









harvested	 by	 centrifugation	 and	 stored	 at	 -80⁰C.	 Cells	 were	 resuspended	 (1g	 in	 4ml)	 in	
25mM	Tris-HCL	pH8.0,	200mM	NaCl,	0.02%	CHAPS,	50mM	L-arginine,	125U	of	Benzonaze®	
(Novagen),	 100mg	 lysozyme	 and	 one	 cOmplete™	 EDTA-free	 protease	 inhibitor	 tablet	
(Roche)	and	lysed	by	sonication.		Insoluble	material	was	removed	by	centrifugation	and	His	
tagged	 protein	 was	 captured	 from	 the	 soluble	 fraction	 by	 immobilised	 metal	 affinity	
chromatography	 (IMAC)	 (HiTrap	 Chelating	 HP,	 GE	 Healthcare)	 eluted	 with	 a	 500mM	
imidazole	 step	 or	 gradient.	 	 The	 6His-Smt	 tag	 was	 removed	 with	 Ubiquitin-like-specific	
protease	 1	 (Ulp-1)	while	 dialyzing	 against	 2	 L	 of	 25	mM	Tris	 pH	 8.0	 and	 200	mM	NaCl	






at	 22°C	 with	 hTNFR1	 at	 1.2,	 2.2,	 3.2	 &	 3.5	 fold	 molar	 excess	 over	 fused	 trimer	 (final	














and	 were	 maintained	 in	 DMEM	 containing	 10%	 FCS	 supplemented	 with	 penicillin	 and	

































4%	 PFA	 in	 PBS	 for	 10min.	 For	 detection	 of	 intracellular	 proteins	 cells	 were	 also	
permeabilized	with	 0.2%	 TritonX-100	 for	 10min	 before	 antibody	 incubation.	 Cells	 were	





(Ibidi)	 were	 washed	 with	 PBS,	 fixed	 with	 4%	 PFA	 in	 PBS	 for	 10min.	 For	 detection	 of	
intracellular	proteins	cells	were	also	permeabilized	with	0.2%	TritonX-100	for	10min	before	
antibody	 incubation.	 Cells	 were	 incubated	 with	 primary	 antibodies	 for	 2hours	 and	
appropriate	 secondary	 antibodies	 conjugated	 to	 alexafluor-488	 or	 alexafluor-568.	 For	







using	 JACoP	 plugin	 in	 FIJI	 (imagej.nih.gov/ij/plugins/track/jacop.html).	 Briefly	





For	 live	 tracking	 of	 TNFR1EmGFP	 clusters	 HeLa	 transfected	 with	 TNFR1-EmGFP	 were	
cultured	in	8	well	glass	bottomed	chambers	(Ibidi)	in	imaging	media	supplemented	with	25	
mM	HEPES.	Images	were	acquired	using	a	Nikon	A1R	microscopy	with	TIRF	capability	using	




was	 written	 in-house	 to	 analysis	 the	 relationship	 between	 cluster	 area	 and	 speed	 of	
movement	 in	 the	 live	 cell	 TIRF	microscopy	 data.	 To	 segment	 the	 images,	we	 followed	 a	
similar	 approach	 to	 that	 described	 in	 (39)	 and	 applied	 wavelet	 filtering	 followed	 by	
watershed	segmentation	to	identify	the	clusters.	After	segmentation	the	centroid	position	
and	 area	 of	 each	 cluster	 can	 be	 determined.	 The	 cluster	 centroids	were	 tracked	 using	 a	
Python	 implementation	 of	 the	 particle	 tracking	 algorithm	 first	 developed	 in	 (40)	

















fluorescence	 is	 collected	 and	de-scanned	where	 it	 is	 directed	with	 a	 dichroic	mirror	 and	
focused	 onto	 the	 Megaframe	 SPAD	 array	 using	 a	 10 × 0.3 N.A.	 Plan	 Fluor	 air	 objective	
(Nikon).	For	each	individual	image	acquisition,	the	system	processed	64 × 64	data	points	for	
8 × 8	detectors	producing	512 × 512	pixel	images.	Lifetime	data	was	acquired	operating	the	





For	 FRET	 experiments	measuring	 TNFR1	 ECD	 conformational	 change	 fibronectin	 coated	
glass	coverslips	of	HeLa-Sh3	transfected	with	HA-TNFR1	were	treated	with	10ng/ml	TNFα	
for	 5min	 before	 fixation	 with	 4%	 PFA.	 Cells	 were	 blocked	 with	 5%	 BSA-PBS	 then	
immunostained	 with	 anti-HA	 antibody	 (Cell	 Signaling)	 diluted	 1in800	 in	 5%	 BSA-PBS	
followed	by	a	Fab	fragment	directly	conjugated	to	Alexafluo-488	secondary	antibody	diluted	
1	 in1000	 in	 1%	BSA-PBS,	without	 cell	 permeabilization.	 Coverslips	were	mounted	 using	
immunofluor.	Time	domain	FLIM	was	performed	with	a	multiphoton	microscope	system	(Ti	
Eclipse	 microscope;	 Nikon)	 described	 in	 detail	 previously	 (42).	 Fluorescence	 lifetime	






fluorescent	 images	were	 acquired	 for	 the	 acceptor	 (DHPE-TexasRed)	 channel	 (DS-Qi1Mc	
camera;	Nikon).	 Lifetime	 raw	data	were	 analyzed	with	 TRI2	 software	 (Paul	 Barber)	 and	
histogram	data	are	plotted	as	mean	FRET	efficiency	from	at	least	30	cells	per	sample	over	
three	 experiments.	 Alexa	 fluor	 488	 has	 been	 previously	 shown	 to	 fit	 to	 a	 biexponential	
lifetime	with	the	longer	lifetime	(43).	Thus,	a	bi-exponential	fluorescence	model	was	used	to	
fit	 the	 data	 using	 in-house	 exponential	 fitting	 software	 (TRI2)	 utilizing	 a	 Levenberg-
Marquardt	algorithm,	with	the	larger	value	interpreted	as	that	of	the	Alexa	488	dye	lifetime.		
Average	 lifetimes	 were	 calculated	 from	 the	 mean	 of	 all	 pixels	 measured	 within	 each	
image/cell	 and	 pooled	 from	multiple	 experiments	 for	 statistical	 analysis.	 All	 graphs	 are	
plotted	 as	 mean	 FRET	 efficiency	 from	 >30	 cells	 in	 total	 pooled	 from	 at	 least	 three	
independent	experiments.	Lifetime	images	of	exemplary	cells	are	presented	using	a	pseudo-
color	scale	whereby	blue	depicts	normal	Alexa	488	lifetime	(i.e.	no	FRET)	and	red	depicts	










































(46)	 and	 subsequently	 analyzing	 the	 local	 localization	density	using	 software	written	 in-

























Fig.	 S3.	 TNFR1	 clusters	 do	 not	 require	 membrane	 microdomains	 or	 cytoskeleton	 for	
assembly	
Fig.	S4.	Analytical	 size	exclusion	chromatography	 (AnSEC)	analysis	of	 titration	of	TNFR1	
with	scTNFα	
Fig.	S5.	Differential	cytokine	release	in	response	to	mutant	scTNFα	binding	
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were	 starved	 (untreated)	 or	TNFa	 treated,	 as	 indicated.	 (B)	TIRFM	 images	 of	HeLa	 cells	
expressing	WT	TNFR1-GFP	and	specified	mutants.	(C)	TIRF	microscopy	analysis	of	TNFR1	
clustering	in	HeLa	cells	co-expressing	TNFR1-GFP	(green)	and	WT	or	mutant	TNFR1-RFP	
(magenta).	 (D)	 FRET	 analysis	 by	 fluorescence	 lifetime	 of	 TNFR1	 dimerization	 in	 cells	
expressing	WT	or	ΔCD	TNFR1-GFP	alone	(donor	alone)	or	co-expressed	with	WT	or	ΔCD	






microscopy	 of	 TNFR1-GFP	 and	 TNFR1-RFP	 expressing	 HeLa	 cells	 before	 and	 after	




experiments.	Quantification	of	 total	GFP	 area	 (C),	 the	percentage	of	GFP	 localized	within	






TIRFM	 analysis	 of	 TNFR1	 clusters	 in	 HeLa	 cells	 expressing	 TNFR1-GFP	 that	were	 TNFa	


























molecules.	 (A)	TIRFM	 analysis	 of	 TNFR1-GFP	 in	 HeLa	 cells	 treated	with	WT	 or	mutant	
TNFa,	as	indicated.	Representative	color-coded	tracks	from	10-minute	movies	are	shown.	
Images	 are	 representative	 of	 3	 independent	 experiments.	 White	 lines	 denote	 plasma	
membrane	boundary	and	color	scale	indicates	track	position	over	time	(black	=	time	0	and	
yellow	=	10	mins).	Quantified	TNFR1-GFP	 cluster	movement	 speed	data	with	medians	 ±	
quartile	values	of	30	cells	are	from	all	experiments.	(B)	Western	blots	for	pp65,	pp38,	and	





from	 HeLacells	 treated	 with	 WT	 or	 mutant	 TNFa. 	 Images	 are	 representative	 of	 3	
independent	experiments.	(E)	TRIFM	analysis	of	TNFR1	(green)	and	MEKK1	(magenta)	in	
TNFR1-GFP	HeLa	cells	treated	with	WT	or	mutBC	TNFa.	Images	(upper)	are	representative	
of	 3	 independent	 experiments.	 White	 lines	 denote	 plasma	 membrane	 boundary.	










(blue).	 Images	 (left)	 are	 representative	 of	 3	 independent	 experiments.	 Quantified	 FRET	
efficiency	data	(right)	are	means	±	SEM	of	30	cells	pooled	from	all	experiments.	(C)	Model	of	
potential	TNFR1	ectodomain	conformational	changes	under	different	ligand	binding	states.	
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(red	 traces),	 and	 combined	 with	 hTNFR1	 over	 a	 range	 of	 ratios	 (TNF	 ,trimer:	 TNFR1):		













forms	 (Bmut,	 red	bars	 and	BCmut,	 green	bars)	 for	 8h.	 Values	 are	 shown	 as	 fold	 change	
over	 untreated	 cells	 over	 the	 same	 time	 period,	 pooled	 from	 duplicate	 arrays	 per	
experiment	and	two	independent	experiments.	Mean	values+/-SEM	are	shown	from	2-way	
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